WILLIAM H. ORRICK, District Judge.
Pursuant to Civil Local Rules 6-2 and 7-12, Plaintiffs Celltrion, Inc., Celltrion Healthcare Co., Ltd., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceuticals International GmbH (collectively, "Plaintiffs") and Defendants Genentech, Inc., Biogen, Inc., Hoffmann La-Roche Inc., and City of Hope (collectively, "Defendants") jointly submit this stipulation regarding Plaintiffs' time to respond to Defendants' Motion to Dismiss. The parties request that the Court approve the Stipulation and enter the proposed order.
WHEREAS, Defendants filed a Motion to Dismiss Pursuant to Federal Rules of Civil Procedure 12(b)(1) and 12(b)(6) in this action on February 28, 2018;
WHEREAS, the current deadlines for the Opposition Brief and Reply Brief are March 14, 2018, and March 21, 2018, respectively;
WHEREAS, counsel for Plaintiffs have multiple case dispositive briefs due the week of April 12, 2018;
WHEREAS, the Motion to Dismiss was Noticed for hearing on April 4, 2018;
WHEREAS, the Initial Case Management Conference has been set for April 10, 2018;
WHEREAS, Lead Counsel for Plaintiffs is unavailable on April 4, 2018 due to a conflict with a previously scheduled trial in a different case;
The parties now STIPULATE as follows:
(1) The deadline for the Opposition Brief shall be extended to
(2) The deadline for the Reply Brief shall be extended to
(3) The hearing date shall be rescheduled to be held on the same date as the Initial Case Management Conference, on either of the dates below, as preferred by the Court:
Pursuant to Civil Local Rule 5-1(i)(3), counsel for Plaintiffs have obtained the concurrence of Defendants' counsel in the filing of this Stipulated Request.